# A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

> **NCT05565742** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 320 (actual)

## Conditions studied

- Lipoprotein Disorder

## Interventions

- **DRUG:** LY3819469
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05565742
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-20
- **Primary completion:** 2023-10-23
- **Final completion:** 2024-10-17
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565742, "A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05565742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*